Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Rhea-AI Summary

Akari Therapeutics (NASDAQ: AKTX) released a Virtual Investor “What This Means” segment on Dec. 18, 2025 featuring President and CEO Abizer Gaslightwala.

The video covers Akari’s spliceosome-modulating payload PH1, new preclinical data for lead ADC AKTX-101 in hard-to-treat KRAS‑mutant pancreatic cancer, and the company’s plan to advance AKTX-101 into clinical testing by late 2026/early 2027. The segment is available to watch online.

Key Figures

Planned clinical start late 2026 / early 2027 Target timing to advance AKTX-101 into clinical testing

Market Reality Check

$0.2824 Last Close

Volume Volume 1,876,221 vs 20-day average 1,601,591 (relative volume 1.17), showing modestly elevated trading ahead of the segment. normal

Technical Shares trade below the 200-day MA, at $0.2505 vs 200-day MA of $0.99, and sit far below the $1.73 52-week high.

Peers on Argus 1 Down

AKTX was down 1.22% pre‑news while only one scanned peer (RNTX) showed downside momentum and others were mixed, indicating a stock-specific setup rather than a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Equity financing	Negative	-38.3%	Dilutive registered direct offering and private placement raising about $5M.
Dec 09	Preclinical data	Positive	+3.2%	Preclinical data showing AKTX-101 potency in KRAS-mutant pancreatic cancer.
Dec 04	Corporate update	Positive	+1.6%	CEO Corner highlighting PH1 ADC payload platform and AKTX-101 plans.
Nov 25	Investor communication	Positive	+0.9%	CEO Corner segment on ADC innovation and PH1 dual mechanism platform.
Nov 18	Management change	Positive	+12.0%	Appointment of experienced biotech finance leader as interim CFO.

Pattern Detected

Recent news events, whether financing-related, corporate updates or preclinical data, have generally seen price moves that align directionally with the apparent news tone.

Recent Company History

Over the last month, Akari issued multiple updates tied to its ADC platform and financing. On Nov 18, a new interim CFO with substantial biotech finance experience was appointed, followed by several communications around the novel PH1 payload and lead ADC AKTX-101 on Nov 25, Dec 4, and Dec 9. A financing on Dec 16 led to a sizeable negative reaction. Today’s investor video segment reiterates the same PH1/AKTX-101 story and timelines rather than introducing a new clinical milestone.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-07-29

Akari has an active S-3 shelf registration filed on 2025-07-29, currently noted as not yet effective, with an expiration on 2028-07-29. The shelf has been used at least 2 times via recent 424B5 prospectus supplements on 2025-12-17 and 2025-10-16, indicating an established mechanism for future capital raises if conditions allow.

Market Pulse Summary

This announcement centers on a Virtual Investor segment explaining Akari’s ADC platform, its spliceosome‑modulating PH1 payload, and the preclinical promise of lead candidate AKTX-101 in KRAS‑mutant pancreatic cancer, with clinical testing targeted for late 2026/early 2027. In context, investors may weigh this communication against recent equity financings, Nasdaq listing compliance issues, and going‑concern language in filings when assessing the overall risk–reward profile.

Key Terms

antibody drug conjugates (ADCs) medical

"an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs)"

Antibody drug conjugates (ADCs) are specialized medicines that combine a targeted antibody with a powerful drug, designed to attack specific disease cells while minimizing harm to healthy ones. This approach allows for more precise treatment, often leading to better outcomes. For investors, ADCs represent innovative therapies with the potential for significant market impact and growth in the healthcare sector.

spliceosome medical

"discussed the Company’s novel spliceosome modulating payload, PH1"

A spliceosome is a cellular molecular machine that edits raw messenger RNA by cutting out noncoding segments and joining the remaining pieces so genes produce the correct proteins. Think of it as an editor or scissors that shapes the final instructions a cell uses. It matters to investors because drugs or tests that affect or measure spliceosome activity can change disease outcomes, create new therapies, or serve as biomarkers, influencing biotech valuations and clinical prospects.

payload medical

"novel spliceosome modulating payload, PH1, and Akari’s ongoing efforts"

Payload is the active substance or cargo carried by a delivery system — for example, the drug molecule attached to an antibody, the gene in a viral vector, or instruments aboard a satellite. Investors care because the payload determines the product’s therapeutic effect, safety profile, manufacturing complexity, regulatory hurdles and commercial value; like the contents of a sealed package, the delivery method matters, but the payload is what buyers ultimately want.

KRAS-mutant medical

"lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer"

A KRAS-mutant tumor carries a change in the KRAS gene that makes cells behave as if a growth “gas pedal” is stuck down, driving uncontrolled cancer growth. For investors, this matters because KRAS mutations define a specific patient subgroup, influence how well therapies work, and determine whether targeted drugs or diagnostic tests will be needed — all of which affect the size of the market, clinical trial results, and regulatory prospects.

AI-generated analysis. Not financial advice.

Watch the “What This Means” video here

TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment.

As part of the segment, Mr. Gaslightwala discussed the Company’s novel spliceosome modulating payload, PH1, and Akari’s ongoing efforts to demonstrate the potential of using this ADC payload against some of the toughest cancers to treat today. This segment highlights the recently announced new preclinical data that demonstrates the therapeutic potential of Akari's lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer. The new data builds on the future development potential of AKTX-101 in a broad range of difficult cancers as Akari works to advance this molecule into clinical testing by late 2026/early 2027.

The Virtual Investor "What This Means" segment featuring Akari is now available here.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements 

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com

FAQ

What did Akari Therapeutics announce in the Dec. 18, 2025 Virtual Investor segment for AKTX?

Akari presented new preclinical data for its lead ADC AKTX-101 and discussed the PH1 payload and plans for clinical testing by late 2026/early 2027.

How does the Dec. 18, 2025 update affect AKTX-101's development timeline (AKTX)?

The segment reiterated the company's aim to advance AKTX-101 into clinical testing by late 2026/early 2027.

What cancer indication did Akari highlight for AKTX-101 in the Dec. 18, 2025 video?

The company highlighted preclinical therapeutic potential of AKTX-101 in KRAS‑mutant pancreatic cancer.

Who spoke for Akari Therapeutics in the Dec. 18, 2025 Virtual Investor 'What This Means' segment?

The segment featured Abizer Gaslightwala, President and CEO of Akari Therapeutics.

Where can investors watch the Akari Therapeutics Dec. 18, 2025 Virtual Investor segment about AKTX?

The company stated the Virtual Investor 'What This Means' segment is now available to watch online via the posted video link.